SEC Form 4 · accession 0001628280-26-048655
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Peetz
Director
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 4:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 15, 2026 | A | 4,315 | $0.00 | A | 4,315 | D | |
| Common StockF2 | holding | — | — | — | 187,500 | I | By The Peetz Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $27.78 | Jul 15, 2026 | A | 21,486 | A | — | Jul 15, 2036 | Common Stock | 21,486 | 21,486 | D |
| Stock Option (right to buy)F4 | $27.78 | Jul 15, 2026 | A | 13,010 | A | — | Jul 15, 2036 | Common Stock | 13,010 | 13,010 | D |
Explanation of responses
- F1Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.
- F2Shares held by The Peetz Family Trust dated February 15, 2017, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- F31/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of July 15, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.
- F4The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.